NVE Corporation Reports Second Quarter Results and Announces Quarterly Dividend

NVE Corporation reported fiscal Q2 2027 revenue down 8% year over year to $5.83 million, from $6.35 million. Product sales fell 9%, partly offset by a 25% rise in contract R&D revenue; net income decreased 4% to $3.17 million, or $0.65 per share.

Analysis

The key question is whether contract R&D is cushioning a temporary product-sales pause or masking weakening product demand. The revenue mix shift could support near-term earnings, but its investment value depends on whether contract work is recurring, converts to commercial product revenue, and carries comparable economics; the release does not establish any of those points. Net income holding up better than revenue is a partial buffer, not proof that product-level profitability is intact.

Near term, expect the market reaction to hinge on the full filing, guidance, and any commentary on product orders or customer concentration. Over the next 1–3 months, watch for a rebound in product sales and evidence that R&D contracts renew or lead to programs. Over 6–18 months, persistent product weakness would raise the risk that contract activity is not replacing scalable product demand. The contrarian read is that modest earnings resilience may be over-weighted if investors focus on the bottom line and under-weight the revenue mix; conversely, one quarter is insufficient to establish structural deterioration. No valuation, liquidity, or consensus data are provided, so conviction in a directional trade is low.

Key Decisions for Investors

• Avoid chasing a directional position on this release alone; first review the complete filing for guidance, product backlog or order indicators, customer concentration, and segment-level gross margins.
• Treat NVEC as a watch item for the next 1–3 months: a product-sales recovery alongside contract renewals would weaken the bearish mix-shift thesis; continued product declines or weaker guidance would strengthen it.
• For existing exposure, reassess risk if subsequent reporting shows product demand deteriorating without repeatable contract R&D revenue. Do not infer recurring revenue or commercial conversion from the reported contract-growth figure alone.
• There is no well-grounded peer pair or options trade from the available information; verify trading liquidity and valuation before considering any position.